Mar 12 2010
Tranzyme Pharma announced today that data from the Phase 2 clinical
trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis
have been selected for an oral presentation at Digestive Disease Week
(DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
“There are
limited therapeutic options to treat this serious medical condition and
the clinical community is eagerly awaiting a new safe and effective
prokinetic therapy.”
Ulimorelin has previously shown the ability to enhance gastric emptying
in patients with severe diabetic gastroparesis. The present analysis
focused on the ability of this drug to relieve nausea and vomiting,
which are the most serious and potentially life-threatening
complications of this disorder. Consistent with its effects on gastric
emptying, ulimorelin significantly reduced nausea and vomiting and
improved overall symptomatology. These results further support
ulimorelin’s future role in the effective management of this
debilitating condition.
“We are very pleased that the study results have been selected for
presentation at this esteemed forum,” said Gordana Kosutic, M.D., Vice
President, Clinical and Regulatory Affairs for Tranzyme. “There are
limited therapeutic options to treat this serious medical condition and
the clinical community is eagerly awaiting a new safe and effective
prokinetic therapy.”
The presentation will be given by Richard McCallum, M.D., Professor and
Founding Chairman of the Department of Internal Medicine, Texas Tech
University Health Sciences Center at El Paso, and a Clinical Advisory
Board member of Tranzyme, at the Neurogastroenterology and Motility
Distinguished Abstract Plenary Session on Monday, May 3rd at
4:15pm EDT in Rooms 283-285 of the Ernest N. Morial Convention Center.
Source Tranzyme Pharma
Is medical cannabis treatment associated with improvements in health-related quality of life?